Acute T cell leukemia. Adult T-cell lymphoma/leukemia (HTLV-1-associated)
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, the Hyper CVAD drug regimen is performed in alternating cycles A and B. Cycle A: Cyclophosphamide 300 mg / m2 every 12 hours on days 1, 2
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Having acute ATL Being over 18 years of age Having a positive HTLV-I serological test result performed with ELISA
Exclusion criteria
Exclusion criteria: Taking drugs that interfere with the treatment regimens used Withdrawing from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission. Timepoint: Weekly from before the intervention (beginning of the study) to 60 days after the intervention. Method of measurement: Based on complete response to treatment (Achieving remission or not getting remission) Through chemical tests and CBC.;One-year survival. Timepoint: On a daily basis from before the intervention (beginning of the study) to 60 days after the intervention. Method of measurement: Based on the individuals’ survival rate (Calculate the number of days to survive until death) Through the occurrence of death in two groups. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa Kamandi
Mashhad University of Medical Sciences
Outcome results
None listed